Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?
MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.
Zacks·12d ago
More News
Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?
Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.
Zacks·1mo ago
All You Need to Know About Verona Pharma (VRNA) Rating Upgrade to Buy
Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·2mo ago
Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?
MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.
Zacks·2mo ago
Merck Stock Down 4% Since Q2 Results: How to Play the Stock
Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.
Zacks·2mo ago
Volatility-Proof Your Portfolio With VIPS, GDS, FUTU & VRNA Stocks
Shield your portfolio from market swings with low-beta picks like VIPS, GDS, FUTU and VRNA, each showing strong momentum.
Zacks·3mo ago
Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?
MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.